

癌症類別	大腸直腸癌
<b>Neoadjuvant CCRT</b>	<p><b>only for CCRT , for "local" rectal cancer :</b>                      (1) 5-FU 425 mg/m<sup>2</sup> (N/S 500 c.c.; 4hrs )+ Leucovorin 100 mg (N/S 500 c.c.; 4hrs ) /wk (JCO 1986; 4: 685-96)                      (2) UFUR 900-1100 mg/ m<sup>2</sup>/d + Leucovorin(P.O.) 30 mg/d</p>
<b>Neoadjuvant</b>	<p><b>Neoadjuvant C/T for colon cancer with invasion of adjacent structures :</b>                      (1)( 5-FU 1300 mg /m<sup>2</sup>/d+ LV 200 mg/m<sup>2</sup>/d ) N/S 500 c.c./d C.I. 2 days q 2wks (JCO 1997; 15: 808-15)                      (2) 5-FU 600 mg /m<sup>2</sup> (N/S 500 c.c. ; ≥3hrs) + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk (JCO 1989; 7: 1407-17)                      (3) UFUR 900-1100 mg/m<sup>2</sup>/d + LV(P.O.) 30mg/d                      (4) (自費)Oxaliplatin 85 mg / m<sup>2</sup> (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV (劑量同上) q 2wks                      (或以 UFUR/LV (dose 同上) 或 Capecitabine 1250-1500 mg/ m<sup>2</sup>/d (2:1 or 5:2) 替代 V.5-FU )                      (Eur J.Cancer 1995; 31(S5))</p>
<b>Adjuvant</b>	<p><b>(I) Colorectal cancer , T ≥ subserosa or pericorectal tissues 且 LN(-) :</b>                      (1)( 5-FU 1300 mg /m<sup>2</sup>/d+ LV 200 mg/m<sup>2</sup>/d ) N/S 500 c.c./d C.I. 2 days q 2wks × 12 doses (JCO 1997; 15: 808-15)                      (2) 5-FU 600 mg /m<sup>2</sup> (N/S 500 c.c. ; ≥3hrs) + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 24 doses (JCO 1989; 7: 1407-17)                      (3) UFUR 900-1100 mg/m<sup>2</sup>/d + LV(P.O.) 30mg/d × 6 months (使用期限可依健保給付規定 ; ≤ 2 years)</p> <p><b>(II) Colorectal cancer , stage III :</b>                      (1)( 5-FU 1300mg /m<sup>2</sup>/d+ LV 200 mg/m<sup>2</sup>/d ) N/S 500 c.c./d C.I. 2 days q 2wks × 24 doses                      (2) 5-FU 600 mg /m<sup>2</sup> + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 48 doses                      (3) UFUR 900-1100 mg/m<sup>2</sup>/d + LV(P.O.) 30mg/d × 12 months (使用期限可依健保給付規定; for stage II, III only, ≤ 2 years)                      (4) Capecitabine 1250-1500 mg/ m<sup>2</sup>/d (2:1 or 5:2) × 6 months (Oncology Jan. 02, 2001)                      (使用期限可依健保給付規定 ; for stage III ; ≤ 8 months )                      (5) Oxaliplatin 85 mg / m<sup>2</sup> (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV (劑量同上) q 2wks x 12 doses                      (或以 UFUR/LV (dose 同上) 或 Capecitabine (dose 同上) 替代 V.5-FU )                      (Eur J.Cancer 1995; 31(S5))</p> <p><b>(III)M0,anyT or N with high risk(s) :</b>                      (1)( 5-FU 1300mg /m<sup>2</sup>/d+ LV 200 mg/m<sup>2</sup>/d ) N/S 500 c.c./d C.I. 2 days q 2wks × 24 doses                      (2) 5-FU 600 mg /m<sup>2</sup> + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 48 doses                      (3) UFUR 900-1100 mg/m<sup>2</sup>/d + LV(P.O.) 30mg/d × 12 months (使用期限可依健保給付規定; ≤ 2 years)</p>

	<p>(4) Capecitabine 1250-1500 mg/ m<sup>2</sup>/d (2:1 or 5:2) × 6 months (Oncology Jan. 02, 2001) (使用期限可依健保給付規定；for stage III；≤ 8 months)</p> <p>(5) Oxaliplatin 85 mg / m<sup>2</sup> (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV (劑量同上) q 2wks x 12 doses (或以 UFUR/LV (dose 同上) 或 Capecitabine (dose 同上)替代 V.5-FU) (Eur J.Cancer 1995; 31(S5))</p> <p>★<b>High risk factors</b> : poorly differentiated carcinoma、lymphatic/vascular invasion、perineural invasion、(near)bowel obstruction、bowel perforation、invasion of visceral peritoneum or adjacent tissue、≤11 lymph nodes sampled、margin positive or close (≤ 1mm)。</p>
<p><b>Palliative</b></p>	<p><b>Colorectal cancer、Stage IV :</b></p> <p>(1)( 5-FU 1300 mg /m<sup>2</sup>/d+ LV 200 mg/m<sup>2</sup>/d ) N/S 500 c.c./d C.I. 2 days q 2wks</p> <p>(2) 5-FU 600 mg /m<sup>2</sup> + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk</p> <p>(3) UFUR 900-1100 mg/m<sup>2</sup>/d+LV(P.O.) 30mg/d</p> <p>(4) Capecitabine 1250-1500 mg/ m<sup>2</sup>/d ( 2:1 or 5:2 )</p> <p>(5) Oxaliplatin 85 mg / m<sup>2</sup> (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV(劑量同 Adjuvant) q 2wks (或以 UFUR/LV (dose 同上)或 Capecitabine (dose 同上)替代 V.5-FU) ( Cancer Treat Rev. 2006 Nov; 32 (7): 491-503)</p> <p>(6) Irinotecan 140,150,160 mg/ m<sup>2</sup> (N/S 500 c.c. ; 3 hrs)+5-FU / LV (劑量同 Adjuvant) q 2wks (或以 UFUR/LV (dose 同上)或 Capecitabine (dose 同上)替代 V.5-FU)</p> <p>(7) Bevacizumab 5mg/kg/dose (N/S 100 c.c. ; 20 mins) (健保條例:可合併(1)~(6))</p> <p>(8) Ramucirumab 8 mg/kg/dose (N/S 300 c.c. ; 90 mins)(自費)</p> <p>(9) Cetuximab 250 mg/m<sup>2</sup>/dose ( 2 hrs) (健保條例:可合併(5)或(6))</p> <p>(10) Panitumumab 6 mg/kg/dose (N/S 100 c.c.; 2 hrs) (健保條例:可合併(5)或(6))</p> <p>(11) Regorafenib 160 mg/d ( 3:1 ) (健保條例)</p> <p>(12) (自費)Tegafur &amp; Gimeracil &amp; Oteracil (TS-1) (2:1) : BSA &lt; 1.25 m<sup>2</sup> : 40 mg bid ; BSA : 1.25-1.5 m<sup>2</sup> : 50 mg bid ; BSA ≥ 1.5 m<sup>2</sup> : 60 mg bid ; (ASCO Jun 6, 2013)</p> <p>(13) Lonsurf 35 mg/ m<sup>2</sup> bid (D1~5,D8~12) / q 28d</p> <p>(14) Pembrolizumab 200mg q 3 wks (依健保規範)</p>

Immunotherapy: PD-1, PD-L1 抑制劑 (如 atezolizumab、nivolumab、Pembrolizumab、ipilimumab；durvalumab；tremelimumab)健保條例